ALNYLAM PHARMACEUTICALS, INC. (ALNY) stock intrinsic value fair value estimate & owner earnings analysis

Alnylam Pharmaceuticals develops and sells RNA interference (RNAi) therapeutics -- drugs that silence disease-causing genes. After many years of R&D investment, the company crossed a real turning point in 2025: for the first time, its cash-generating power turned solidly positive after stripping out the effect of employee stock compensation and working-capital swings. That inflection is the foundation of this valuation. The company sells four of its own approved drugs directly -- AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, all treatments for rare genetic diseases -- and earns royalties on two more sold by partners: Leqvio (inclisiran), a cholesterol-lowering drug marketed globally by Novartis, and Qfitlia (fitusiran), a hemophilia drug approved by the FDA in March 2025 and marketed by Sanofi. Combined product revenue reached roughly $3.0 billion in 2025, up 81% from 2024, and total revenue (including royalties and collaboration payments from partners funding Alnylam's pipeline) reached $3.7 billion. The single biggest driver of that growth was AMVUTTRA's March 2025 FDA approval for a much larger use: transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition, on top of its original nerve-disease indication. AMVUTTRA's U.S. sales nearly tripled from 2024 to 2025 on the back of that approval, but it is still early in that launch (only about ten months of sales by year-end 2025) and is competing against two well-established oral rivals: Pfizer's tafamidis (Vyndaqel/Vyndamax) and BridgeBio's newer acoramidis (Attruby). We treat that as a real headwind, not a footnote -- it is the main reason our base case assumes AMVUTTRA's growth cools from its 2025 pace rather than continuing at that rate indefinitely. What we did with the accounting: Alnylam's cash flow from operations was $524 million in 2025, its first meaningfully positive year in a long time. But operating cash flow on its own overstates what the business is really generating, for two reasons we corrected for. First, stock-based compensation was $348 million in 2025 (and has grown every year since 2016) -- that is a real cost of running the business, paid in shares instead of cash, so we treat it as an expense rather than letting the cash-flow statement ignore it. Second, a $360 million buildup in receivables as sales grew quickly flattered the reported cash flow; we stripped that out, along with all other working-capital swings, so the number reflects sustainable earning power rather than one year's timing. After those adjustments, and after setting aside a reasonable estimate of the capital spending needed just to sustain the business (rather than fund its next stage of growth), Alnylam generated about $594 million, or $4.41 per diluted share, in underlying owner earnings in 2025 -- the first year that figure has been positive. Every year from 2016 through 2024 was negative on this basis, some deeply so (over $9 per share of cash consumption in 2019, for example), the normal signature of a company building a drug pipeline and its own manufacturing and sales infrastructure before it had enough approved products to cover the cost. We used 2025 alone as the basis for this valuation rather than blending it with the loss-making years before it, because those years describe a fundamentally different company -- one without a marketed-drug portfolio generating cash. We checked that the 2025 level is holding up, not a one-off: cash from operations in the first half of 2026 was already $397 million, about 76% of all of 2025, on revenue growth of roughly 80% year-over-year. One accounting detail matters for how durable this looks going forward. In 2020, Alnylam sold Blackstone Life Sciences half of its future Leqvio royalty stream for $1 billion upfront. That transaction is treated as debt on Alnylam's books, and the annual 'interest' on it (a non-cash expense) is added back in our earnings calculation, which is standard treatment. But it means a real economic cost -- giving up half the Leqvio royalty going forward -- doesn't reduce our earnings figure directly; it shows up as leverage on the balance sheet instead ($1.69 billion of these royalty-monetization liabilities were outstanding at year-end 2025, plus convertible notes from a 2025 refinancing). Consistent with how we treat debt generally, we did not subtract this from the value directly, but it makes the downside case worse, since a real chunk of future cash flow is already spoken for. Separately: if cumulative payments to Blackstone don't reach $1 billion by the end of 2029, Alnylam's share of the Leqvio royalty drops from 50% to 45% starting in 2030 -- a specific, dated risk built into the bear case. The bear case assumes AMVUTTRA's cardiomyopathy launch grows only modestly against entrenched competition, the 2030 Leqvio royalty step-down actually happens, and stock-based compensation keeps growing roughly as fast as revenue rather than easing. Owner earnings grow at a mid-single-to-low-double-digit pace through the 2030s, and we assume today's approved-product franchise gradually loses roughly half its earning power to patent and competitive erosion over time without much being replaced. That produces a value of roughly $74 per share. The base case assumes AMVUTTRA's cardiomyopathy use continues to ramp but at a decelerating rate as the initial launch surge normalizes, GIVLAARI and OXLUMO keep growing in the high teens as they have for several years, Leqvio's royalty keeps building as Novartis expands into more of the countries where the drug is registered, and Qfitlia begins a multi-year hemophilia launch. We assume the earning power that exists ten years out gets partially eroded by patent and competitive pressure in the years after, but Alnylam's approval record -- six drugs approved since 2018, a demonstrated and repeatable track record -- supports some of that being replaced by newer products. That produces a value of roughly $159 per share. The bull case assumes execution continues closer to the pace actually delivered in 2025 -- AMVUTTRA's U.S. sales nearly tripled that year and international sales grew comparably fast -- for several more years as the cardiomyopathy launch matures, with Leqvio's royalty staying at the full 50% share. The compounding from there is substantial: roughly $310 per share. What we did not include: Alnylam has more than 20 other programs in its pipeline, including some in late-stage trials, but none had reported positive pivotal results as of this filing. We assigned those zero value in every case -- not a discount, zero -- because a drug that hasn't cleared a late-stage trial is a possibility, not evidence of future cash flow. A positive readout would be new information to revisit, not something to price in now. What could be wrong here: this valuation leans heavily on 2025 being a real, durable turning point rather than just a good year. The first-half-2026 results support that, but it is still under two years of evidence following close to a decade of losses. We also could not find a specific patent-expiration date for any of Alnylam's individual drugs in the filings we reviewed, so exactly when today's franchise starts shrinking is genuinely unresolved -- we handled that by assuming meaningful erosion in every case rather than assuming these products earn at today's level forever, but a specific date would sharpen this considerably. Given this is a very recent inflection resting substantially on one indication expansion against real competition, the margin-of-safety price carries a wide cushion: near $87 per share, roughly 45% below our base-case estimate and close to our bear-case figure, the level at which we estimate the risk of a disappointing outcome is adequately reflected.